Loading...
Market
Pfizer stock performance relative to S&P 500 by end of 2024?
3
Resolution / Starting Odds
Outperforms S&P 500 • 25%
Matches S&P 500 • 25%
Underperforms S&P 500 • 25%
Significantly underperforms • 25%
Stock market data from reliable financial sources
Story
Former Pfizer Executives Withdraw Support from Starboard's $1 Billion Activist Campaign Targeting Albert Bourla
Oct 10, 2024, 03:58 AM
Pfizer is currently facing activist pressure from Starboard Value, which has recently acquired $1 billion in Pfizer shares. The activist campaign has targeted Pfizer's CEO, Albert Bourla, criticizing the company's lack of focus, despite the company momentarily surpassing the $100 billion mark. However, in a surprising turn of events, former Pfizer executives Ian Read and Frank D'Amelio, who were initially associated with Starboard's efforts, have withdrawn their support for the campaign. They have publicly declared their full support for Bourla and the existing senior management team. Additionally, Pfizer's stock fell 1% following the announcement, and Starboard issued a letter to Pfizer’s board criticizing alleged coercive conduct towards former executives.
View original story
Similar markets
Outperform by more than 5% • 25%
Perform within 5% of S&P 500 • 25%
Underperform by 1-5% • 25%
Underperform by more than 5% • 25%
Outperforms by more than 5% • 25%
Outperforms by 0% to 5% • 25%
Underperforms by 0% to 5% • 25%
Underperforms by more than 5% • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
Outperforms all • 25%
Outperforms some • 25%
Matches performance • 25%
Underperforms all • 25%
Less than $150 billion • 25%
$150 billion to $170 billion • 25%
$170 billion to $190 billion • 25%
More than $190 billion • 25%